JP2009507073A5 - - Google Patents

Download PDF

Info

Publication number
JP2009507073A5
JP2009507073A5 JP2008530093A JP2008530093A JP2009507073A5 JP 2009507073 A5 JP2009507073 A5 JP 2009507073A5 JP 2008530093 A JP2008530093 A JP 2008530093A JP 2008530093 A JP2008530093 A JP 2008530093A JP 2009507073 A5 JP2009507073 A5 JP 2009507073A5
Authority
JP
Japan
Prior art keywords
substituted
aryl
group
heterocycloalkyl
alkylheterocycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008530093A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009507073A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/033686 external-priority patent/WO2007030362A1/en
Publication of JP2009507073A publication Critical patent/JP2009507073A/ja
Publication of JP2009507073A5 publication Critical patent/JP2009507073A5/ja
Pending legal-status Critical Current

Links

JP2008530093A 2005-09-07 2006-08-28 子宮内膜症の治療のためのｉｋｋ阻害剤 Pending JP2009507073A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US71464505P 2005-09-07 2005-09-07
EP05109450 2005-10-11
PCT/US2006/033686 WO2007030362A1 (en) 2005-09-07 2006-08-28 Ikk inhibitors for the treatment of endometriosis

Publications (2)

Publication Number Publication Date
JP2009507073A JP2009507073A (ja) 2009-02-19
JP2009507073A5 true JP2009507073A5 (enExample) 2009-10-15

Family

ID=37663766

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008530093A Pending JP2009507073A (ja) 2005-09-07 2006-08-28 子宮内膜症の治療のためのｉｋｋ阻害剤

Country Status (10)

Country Link
US (1) US20100069387A1 (enExample)
EP (2) EP1931322B1 (enExample)
JP (1) JP2009507073A (enExample)
KR (1) KR20080052650A (enExample)
CN (1) CN101304736A (enExample)
AU (1) AU2006287767B2 (enExample)
CA (1) CA2621057A1 (enExample)
EA (1) EA200800755A1 (enExample)
IL (1) IL189659A0 (enExample)
WO (1) WO2007030362A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2303841A1 (en) 2008-07-14 2011-04-06 Gilead Sciences, Inc. Oxindolyl inhibitor compounds
EP2303881A2 (en) 2008-07-14 2011-04-06 Gilead Sciences, Inc. Fused heterocyclyc inhibitors of histone deacetylase and/or cyclin-dependent kinases
JP5640005B2 (ja) 2008-07-14 2014-12-10 ギリアード サイエンシーズ， インコーポレイテッド Ｈｄａｃおよび／またはｃｄｋ阻害剤としてのイミダゾシルピリジン化合物
KR20110038159A (ko) 2008-07-28 2011-04-13 길리애드 사이언시즈, 인코포레이티드 사이클로알킬리덴 및 헤테로사이클로알킬리덴 히스톤 데아세틸라아제 억제제 화합물
CN101503402B (zh) * 2009-03-10 2014-06-25 沈阳药科大学 2-苯胺嘧啶衍生物及其制备和用途
CA2763786C (en) 2009-06-08 2014-09-30 Gilead Sciences, Inc. Alkanoylamino benzamide aniline hdac inihibitor compounds
ES2463826T3 (es) 2009-06-08 2014-05-29 Gilead Sciences, Inc. Compuestos inhibidores de HDAC de cicloalquilcarbamato benzamida anilina
CN105132529A (zh) 2009-07-24 2015-12-09 吉第克生物技术有限公司 子宫内膜癌的标记物
AU2011260323A1 (en) 2010-06-04 2012-11-15 F. Hoffmann-La Roche Ag Aminopyrimidine derivatives as LRRK2 modulators
KR101566091B1 (ko) 2010-11-10 2015-11-04 에프. 호프만-라 로슈 아게 Lrrk2 조절제로서 피라졸 아미노피리미딘 유도체
WO2019169113A1 (en) * 2018-03-02 2019-09-06 Ponce Medical School Foundation, Inc. Compositions and methods for the treatment of endometriosis
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
WO2020168197A1 (en) 2019-02-15 2020-08-20 Incyte Corporation Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
TW202100520A (zh) 2019-03-05 2021-01-01 美商英塞特公司 作為cdk2 抑制劑之吡唑基嘧啶基胺化合物
US11919904B2 (en) 2019-03-29 2024-03-05 Incyte Corporation Sulfonylamide compounds as CDK2 inhibitors
WO2020223558A1 (en) 2019-05-01 2020-11-05 Incyte Corporation Tricyclic amine compounds as cdk2 inhibitors
WO2020223469A1 (en) 2019-05-01 2020-11-05 Incyte Corporation N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer
WO2021030537A1 (en) 2019-08-14 2021-02-18 Incyte Corporation Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors
CR20220170A (es) 2019-10-11 2022-10-10 Incyte Corp Aminas bicíclicas como inhibidoras de la cdk2
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
CN119769990B (zh) * 2024-12-26 2025-09-09 大连医科大学附属第二医院 子宫内膜异位症的检测系统和治疗剂

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4923805A (en) 1983-11-02 1990-05-08 Integrated Genetics, Inc. Fsh
DE10199028I2 (de) 1983-11-02 2004-07-01 Applied Research Systems Produkte und Methoden für die Herstellung einer heterodimerer menschlicher LH mit einem Met42 Val55 alpha Untereinheit.
IT1206302B (it) 1987-06-26 1989-04-14 Serono Cesare Ist Ricerca Ormone follicolo-stimolante urinario
JP2002193938A (ja) * 2000-12-01 2002-07-10 Bayer Ag ４−アリールピリジン誘導体
US7122544B2 (en) * 2000-12-06 2006-10-17 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto
US20030134836A1 (en) * 2001-01-12 2003-07-17 Amgen Inc. Substituted arylamine derivatives and methods of use
CZ20032287A3 (cs) * 2001-02-01 2004-02-18 Bristol-Myers Squibb Company Způsoby léčení zánětlivých a imunitních nemocí za použití inhibitorů IkB kinázy (IKK)
SE0102616D0 (sv) * 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
WO2003015820A1 (en) * 2001-08-10 2003-02-27 Takeda Chemical Industries, Ltd. GnRH AGONIST COMBINATION DRUGS
DE10237722A1 (de) 2002-08-17 2004-08-19 Aventis Pharma Deutschland Gmbh Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase
WO2004048343A1 (en) * 2002-11-28 2004-06-10 Schering Aktiengesellschaft Chk-, pdk- and akt-inhibitory pyrimidines, their production and use as pharmaceutical agents
EP1670908A2 (en) * 2003-10-02 2006-06-21 Xantos Biomedicine AG Medical use of tbk-1 or of inhibitors thereof

Similar Documents

Publication Publication Date Title
AU2021282467B2 (en) AR+ breast cancer treatment methods
JP6193922B2 (ja) ハロアルキルヘテロアリールベンズアミド化合物
JP2007519649A5 (enExample)
AU2013215251A1 (en) Combination of a RTK inhibitor with an anti - estrogen and use thereof for the treatment of cancer
AU2006287767B2 (en) IKK inhibitors for the treatment of endometriosis
RU2013143028A (ru) Тиазолилфенилбензолсульфонамидопроизводные в качестве ингибиторов киназ
JP2012510989A5 (enExample)
JP2010513448A5 (enExample)
CN103052388A (zh) σ配体在阿片类药物诱导的痛觉过敏中的应用
CA2669128A1 (en) Treatment for multiple myeloma
AR068947A1 (es) Inhibidor de la proteina activadora de la 5- lipoxigenasa (flap), composiciones farmaceuticas, sales y solvatos
JP2012515787A5 (enExample)
JP2013532709A5 (enExample)
CZ321094A3 (en) Pharmaceutical preparation for inhibiting non-functional uterus bleeding
KR20020090153A (ko) 알콜중독 또는 알콜 의존을 위한 배합 치료
JP2009501745A5 (enExample)
JP2016027024A5 (enExample)
WO2013009812A1 (en) Methods of treatment
RU2016133285A (ru) Фармацевтические комбинации
JP2015502386A5 (enExample)
JP2017502989A5 (enExample)
JP2022517517A5 (enExample)
CN109863144A (zh) 用于治疗子宫内膜异位的新型吲哚衍生物
AU2006270184B2 (en) JNK inhibitors for the treatment of endometreosis
WO2014058785A1 (en) Combination therapy